Loading, Please Wait...
CEO to Discuss Initial Stage of the Global Commercialization of His Company’s Proprietary Cannabinoid Delivery System, which Resemble “LISTERINE’S POCKETPACKS®”
BALTIMORE, MD, May 01, 2019 (GLOBE NEWSWIRE) -- Greater Cannabis Company (OTC: GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, is scheduled to be featured in a live interview today at 1:10 pm EST on the Cheddar Financial News Network on the floor of the New York Stock Exchange (NYSE) during trading hours. During today’s segment, the Company’s Chairman and Chief Executive Officer, Aitan Zacharin, is expected to provide a brief summary of the history of Greater Cannabis Company, why and how it was formed and, in particular, its proprietary cannabinoid delivery system, which is anticipated to become one of the most disruptive technologies in cannabis industry since its legalization. Please note the interview can be viewed on the Cheddar.tv website and other services the network streams to., which can be found on its site. A recording of the interview will be available shortly after on the Company’s website.
Cannabis has been increasingly growing in validity and presence among the senior exchanges in the U.S., including NYSE and NASDAQ, as well as the traditional blue-chip investment banks such as the Bank of America, which announced that it will begin providing analyst coverage of the cannabis sector. Additionally, funding for U.S-based cannabis companies is continuing to break historical records.
“2019 thus far has been a banner year for the cannabis industry as major corporations have made the decision to support its rapid emergence and almost immediate growth into a multi-billion-dollar market and, most importantly, find an opportunity to capitalize on what appears to be an industry that haa not shown any signs of slowing,” said Aitan Zacharin, Chief Executive Officer of The Greater Cannabis Company. “Our cannabis oral strips meet a rising, unmet demand for alternative and safe routes of cannabis administration that achieve optimal potency and higher bioavailability,” concluded Zacharin.
Zacharin’s appearance on the Cheddar Financial Network follows several recent advancements by the Company, including its expansion into CBD-infused beauty and cosmetic products, and plans to conduct a new clinical study of its technology’s CBD-absorption. It recently signed a letter of intent (LOI) with Allume Cosmeticos, a leading Brazilian beauty and personal care company, and an LOI with CBR Participacoes SA, one of Brazil’s top pharmacy networks.
Cheddar Financial Network, which was acquired yesterday for $200 million by publicly traded cable operator Altice USA, has rapidly grown to become one of the pioneers in live streaming networks, reaching an approximate 400 million combined viewers a month, including 40 million pay-TV households through distribution relationships. Segments broadcast live across multiple digital channels, including SlingTV, Amazon Prime, Hulu Live, YouTube Live, Facebook Watch, and other platforms. The company, which was among its investors along with AT&T, Goldman Sachs, Comcast Ventures, the NYSE and several other major brands.
Greater Cannabis Company was created by an experienced team of executives and scientists in 2014. Its bio-adhesive, adjustable dose, fully dissolvable and non-irritant patch is designed to accelerate and enhance the delivery and bioavailability of medicines and cannabis actives when compared to traditional methods of enteral administration. The Company combines this with expertise and innovation in concept development to full-scale commercialization.
For more information about Greater Cannabis Company or to invest, visit www.gcanrx.com.
About The Greater Cannabis Company
The Greater Cannabis Company (OTC: GCAN) is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems. Greater Cannabis deploys its patented technology platform for use in the cannabis industry. The Company’s conveyance platform can be utilized to deliver cannabinoids without the harmful side effects found with other routes of cannabinoid administration. The technology is versatile in that for the first-time patients can receive lower dosing, enhanced bioavailability, and controlled rapid and delayed release using a fully dissolvable, non-irritant oral eluting patch. Greater Cannabis’ mission is to bring our technology to the global market through partnerships with leading cannabis and pharmaceutical companies, for the benefit of patients and consumers. More information on the Greater Cannabis Company and its technology can be found on the Company’s website, www.gcanrx.com.
Disclaimer: GCANRx relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve several risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.
The Greater Cannabis Company, Inc.